Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Feb 20, 2024
- Accession no.
- 0000950170-24-017442
- Filed
- Feb 20, 2024
- Trade date
- Feb 15-16, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $822.0K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2024 | Common Stock | MOption exerciseAcquired | +4,760 | $3.29 | +$15,660.4 | 79,215 | Direct | |
| Feb 15, 2024 | Common Stock | SSaleDisposed | −4,760 | $25.00 | −$119,000 | 74,455 | Direct | |
| Feb 16, 2024 | Common Stock | MOption exerciseAcquired | +12,226 | $3.29 | +$40,223.54 | 86,681 | Direct | |
| Feb 16, 2024 | Common Stock | MOption exerciseAcquired | +14,842 | $3.88 | +$57,586.96 | 101,523 | Direct | |
| Feb 16, 2024 | Common Stock | SSaleDisposed | −27,068 | $25.97 | −$702,955.96 | 74,455 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2024 | Common Stock | MOption exerciseDisposed | −4,760 | $0.00 | $0 | 12,226 | Direct | |
| Feb 16, 2024 | Common Stock | MOption exerciseDisposed | −12,226 | $0.00 | $0 | 0 | Direct | |
| Feb 16, 2024 | Common Stock | MOption exerciseDisposed | −14,842 | $0.00 | $0 | 135,158 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
President, Corcept Endocrinology. The power of attorney under which this form was signed is on file with the Commission.